Safety and impact of eculizumab withdrawal in patients with atypical haemolytic uraemic syndrome: protocol for a multicentre, open- label, prospective, single- arm study

HIGHLIGHTS

  • who: Sarah Dunn u200d u200d and collaborators from the Visit details and assessments Baseline assessments and data collection for withdrawal cohort (visit, day, u00b1, days) Study day , will be the day that the participants would usually receive their next dose of eculizumab, based on standard dosing schedules (u00b1, days)The eculizumab will not be administered have published the paper: Safety and impact of eculizumab withdrawal in patients with atypical haemolytic uraemic syndrome: protocol for a multicentre, open- label, prospective, single- arm study, in the Journal: BMJ Open 2022;12:e054536. of /2022/
  • what: In this . . .

     

    Logo ScioWire Beta black

    If you want to have access to all the content you need to log in!

    Thanks :)

    If you don't have an account, you can create one here.

     

Scroll to Top

Add A Knowledge Base Question !

+ = Verify Human or Spambot ?